Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Glasberg J
Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,
Keywords: neuroendocrine tumors, metformin, clinical trial,
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,
Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Custodio A
Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,
Keywords: NET, everolimus, hyperglycemia ,